Skip to main navigation
  • About
    • Our Company
    • Contact
  • Science
    • PIKA Technology Platform
  • Pipeline
    • Our Pipeline
    • Product Candidate
      • Infectious Disease
      • Immuno-Oncology Biotherapeutics
    • Commercial Products
  • Business Development
    • Partnerships
  • Investor Relations
    • Overview
    • News & Events
      • News Releases
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
    • Governance
      • Documents & Charters
      • Board of Directors
      • Management
      • Committee Composition
    • Financials & Filings
      • SEC Filings
    • Resources
      • Investor FAQs
      • Email Alerts
      • Information Request
      • Contact IR
  • Career
    • Working at Yisheng
Menu
  • About
    • Our Company
    • Contact
  • Science
    • PIKA Technology Platform
  • Pipeline
    • Our Pipeline
    • Product Candidate
      • Infectious Disease
      • Immuno-Oncology Biotherapeutics
    • Commercial Products
  • Business Development
    • Partnerships
  • Investor Relations
    • Overview
    • News & Events
      • News Releases
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
    • Governance
      • Documents & Charters
      • Board of Directors
      • Management
      • Committee Composition
    • Financials & Filings
      • SEC Filings
    • Resources
      • Investor FAQs
      • Email Alerts
      • Information Request
      • Contact IR
  • Career
    • Working at Yisheng

News Releases

May 18, 2023
YS Biopharma to Participate in the Virtual Benchmark Healthcare House Call Conference on May 23, 2023
May 16, 2023
YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval in Pakistan
April 18, 2023
YS Biopharma Announces Record Vaccine Revenues and Preliminary Financial Results for FY2023 Ended March 31, 2023
March 27, 2023
YS Biopharma's PIKA Recombinant COVID-19 Vaccine Demonstrates Superior Antibody Neutralization Responses Compared to Inactivated COVID-19 Vaccine in Phase II Head-to-Head Clinical Study
March 16, 2023
YS BIOPHARMA TO RING THE OPENING BELL AND DEBUT ON NASDAQ
March 14, 2023
YS BIOPHARMA AND SUMMIT HEALTHCARE ANNOUNCE SHAREHOLDER APPROVAL OF BUSINESS COMBINATION
February 8, 2023
SUMMIT HEALTHCARE ACQUISITION CORP. AND YS BIOPHARMA ANNOUNCE EFFECTIVENESS OF REGISTRATION STATEMENT AND EXTRAORDINARY GENERAL MEETING DATE FOR PROPOSED BUSINESS COMBINATION
Print Page
Email Alerts
RSS Feeds
Contact IR
Site Map Terms of Use Privacy

Contact Info

YS Biopharma Co., Ltd.

11 Firstfield Road Suite A
Gaithersburg, Maryland 20878 USA

Tel: +1 (301) 208 8823
Fax: +1 (301) 208 8827

bjinfo@yishengbio.com

Copyright © 2023 YS Biopharma Co., Ltd.. All Rights Reserved.